This week in drug discovery (18-22 August)
News round-up for 18-22 August by DDW Senior Digital Content Editor Diana Turner.
The news this week has emphasised the importance of shared knowledge and expertise to the development of new drugs, whether that is through research collaboration agreements or mergers and acquisitions, with a number of new deals across different therapy areas.
The top stories:
Bayer and Kumquat collaborate on precision oncology
Bayer and Kumquat Biosciences have entered into an exclusive global license and collaboration agreement to develop and commercialise Kumquat’s KRAS G12D inhibitor.
10x Genomics expands single cell analysis with Scale buyout
10x Genomics has acquired Scale Biosciences, gaining key inventions and technologies and broadening access to single cell analysis.
Monument Therapeutics partners on novel treatment for schizophrenia
Monument Therapeutics and the Foundation for the National Institutes of Health (FNIH) will evaluate MT1988, in development for cognitive impairment associated with schizophrenia, in a proof-of-principle clinical trial.
Synthetic biology collaboration to develop plant genomics
A collaborative project led by the Max-Planck Institute of Molecular Plant Physiology (MPI-MP), Germany, aims to develop synthetic chloroplast genomes.
Kite acquires in vivo CAR-T developer for $350 million
Gilead-owned Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million.
